Skip to content

A Study of Magnetic Resonance Imaging of the Pancreas for Cancer Screening

Pilot Study of a Dedicated MR of the Pancreas: Improving Screening for Patients at High Risk for Pancreas Cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07612046
Enrollment
79
Registered
2026-05-28
Start date
2026-05-20
Completion date
2028-05-20
Last updated
2026-07-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreas Cancer, Pancreatic Cancer

Keywords

Pancreatic Cancer, Pancreas Cancer, Memorial Sloan Kettering Cancer Center, 26-174

Brief summary

The purpose of this study is to develop a dedicated MRI scan of the pancreas (MRP) to better detect pancreatic cancer in people who are at a high risk for pancreatic cancer.

Interventions

DIAGNOSTIC_TESTMRI

Participants will undergo a single MRI of the abdomen without contrast

DIAGNOSTIC_TESTEndoscopic ultrasound

EUS will be scheduled the same day or within 2 weeks prior to MRP

Sponsors

Memorial Sloan Kettering Cancer Center
Lead SponsorOTHER
National Institutes of Health (NIH)
CollaboratorNIH

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Two first-degree relatives with pancreas cancer, one being a first-degree relative to the individual * Pathogenic mutation in APC, BRCA1, MLH1, MSH2, MSH6, PMS2, EPCAM, PALB2, or TP53 and a first/second-degree relative with pancreas cancer * Pathogenic mutation in CDKN2A/p16, STK11, PRSS1, SPINK1/PST1, CTRC, CPA1, ATM, or BRCA2 * Meets surveillance age eligibility, which is typically age 50, or 10 years earlier than the youngest relative with pancreas cancer. For individuals with certain gene mutations, this can be earlier. All participants must be aged 21+ For this pilot MRP study, we will additionally apply the following Criteria: * Consents to follow-up contact * US residents * Completed MRI with MRCP with no actionable findings related to the pancreas (e.g. a pancreatic mass) * No metallic artifacts covering the pancreas on prior MRCP * Scheduled for endoscopic ultrasound * No new contraindications for MRI (e.g. new MR unsafe device) * No history of claustrophobia or use of anxiolytic on prior MRI * No history of abdominal surgery that may affect interpretation of either EUS or MR * No medical conditions that confers increased and/or unacceptable risk for anesthesia We will recruit surveillance participants who had at least one prior MRCP in the last 3 years. They must also undergo a same-day EUS procedure as part of their surveillance. Nearly all active cohort participants have had at least one recent MRCP and, on average, our Registry gastroenterologist Dr. Rolston performs EUS in \~260 surveillance participants per year. Accordingly, it is highly feasible to recruit more than 79 participants in the grant period, and recruitment is constrained by budget. * Documentation of Disease o No pathologic confirmation of disease is necessary * Definition of Disease N/A * Required Organ Function N/A

Exclusion criteria

\-

Design outcomes

Primary

MeasureTime frameDescription
Compare image quality of novel high-resolution magnetic resonance pancreas (MRP) to conventional MRCPUp to 3 yearsDevelop and pilot a focused high-resolution magnetic resonance pancreas (MRP) exam to help facilitate early pancreatic cancer detection in high-risk individuals. Image quality for T1, T2, and DWI sequences performed on the novel MRP exam will be compared to conventional MRCP performed in the same participants.

Countries

United States

Contacts

CONTACTRichard Kinh Gian Do, MD, PhD
dok@mskcc.org212-639-8591
CONTACTMengmeng Du, ScD
dumeng@mskcc.org646-227-3495
PRINCIPAL_INVESTIGATORRichard Kinh Gian Do, MD, PhD

Memorial Sloan Kettering Cancer Center

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 10, 2026